X

Trial Profile

A preference trial with rizatriptan 10 mg and ibuprofen 400 mg in migraine patients in the general practice

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rizatriptan (Primary) ; Ibuprofen
Indications Migraine
Focus Therapeutic Use
Sponsors Merck Sharp & Dohme

Most Recent Events

26 Jun 2011 Results presented at the 15th Congress of the International Headache Society.
14 Sep 2009 Planned end date 9 Nov 2006 added as reported by Netherlands Trial Register record.
10 Sep 2009 Planned number of patients (35) added, additional trial sponsor Reckitt benckiser added as reported by Netherlands Trial Register record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com